FDA Approves Enlicitid: A New Breakthrough Pill for Cholesterol Reduction

The U.S. Food and Drug Administration (FDA) has approved enlicitida, a new cholesterol-lowering medication developed by Merck, designed to target patients with high levels of low-density lipoprotein (LDL) cholesterol. According to reporting from The New York Times and CNN en Español, the drug provides a new therapeutic option.

Enlicitida functions by inhibiting the activity of angiopoietin-like 3 (ANGPTL3), a protein that regulates the metabolism of lipids in the bloodstream. By blocking this protein, the medication helps the body clear LDL cholesterol—often termed “bad” cholesterol—more efficiently from the blood, according to details provided by Infobae.

The approval targets a specific patient population: those who require more aggressive lipid-lowering strategies.

How Enlicitida Differs from Statins

Most cholesterol treatments rely on statins, which work by blocking the enzyme HMG-CoA reductase in the liver to reduce the production of cholesterol. Enlicitida operates via a different biological pathway. According to Infobae, it focuses on the inhibition of the ANGPTL3 protein, which allows for a reduction in cholesterol levels.

By utilizing a different mechanism of action, enlicitida can lower LDL levels, according to reports from TN and La Nueva España.

Clinical Application and Preventive Medicine

The introduction of enlicitida represents a shift toward a new model of preventive medicine. La Nueva España reports that the drug is positioned as a tool to reduce cholesterol levels in high-risk patients.

The medication is intended for use as an add-on therapy. According to the FDA approval details cited by CNN en Español, it is not meant to replace statins for the general population but to supplement them.

Impact on Cardiovascular Health

High levels of LDL cholesterol contribute to the buildup of plaque in the arteries, a process known as atherosclerosis. When this plaque ruptures, it can cause a blockage that leads to a myocardial infarction or stroke. By lowering these levels, enlicitida aims to stabilize or reduce this plaque buildup, according to medical context provided by Infobae.

The drug’s ability to target the ANGPTL3 pathway allows it to lower not only LDL but also other lipid markers that contribute to cardiovascular risk.

Patient Eligibility and Access

Access to enlicitida will be governed by specific clinical criteria. According to The New York Times, the drug is indicated for patients with severe hypercholesterolemia. This includes individuals with familial hypercholesterolemia and those with established atherosclerotic cardiovascular disease.

Medical providers will determine eligibility based on a patient’s current LDL levels and their history of response to other lipid-lowering therapies. The goal is to bring these patients closer to the targets recommended by cardiovascular guidelines to minimize the likelihood of future cardiac events.